Weight reduction by 24.3%! Novo Nordisk (NVO.US) new generation weight loss drug Amycretin achieves positive results in small-scale trial.

Wisdom Financial APP learned that the latest weight-loss drug developed by Novo Nordisk (NVO.US) helped patients successfully lose weight by 24.3% in a small study. This achievement indicates that the drug is expected to become a new generation of treatment drugs in the competitive market. Researchers published two trial reports in The Lancet, stating that a drug called amycretin showed signs of improving blood sugar levels, with side effects similar to other powerful weight-loss drugs. The trial results will be announced at the American Diabetes Association conference in Chicago. In the trial of the compound in injection form, participants lost 24.3% of their weight within 36 weeks.